OREANDA-NEWS. The Chinese coronavirus vaccine Ad5-nCov may enter the market at the end of December 2020.

This was stated by Liu Jingzhen, the secretary of the party committee, chairman of the board of directors of the state corporation Sinopharm, in an interview with the newspaper Guanming Daily. “After the completion of the third stage of international clinical trials, we can proceed to the stage of approval of the inactivated vaccine. We expect that the vaccine will be able to enter the market by the end of December this year,” Liu Jingzhen said.

China patented the vaccine on August 17. This is a recombinant medication jointly developed by specialists from the company CanSino Biologics and the Institute for Bioengineering Research at the Academy of Military Medical Sciences. Clinical trials of the vaccine began in March. On June 11, the second phase of clinical trials ended.